Mouse Calcoco1 Conditional Knockout Project (CRISPR/Cas9)

Total Page:16

File Type:pdf, Size:1020Kb

Mouse Calcoco1 Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Calcoco1 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Calcoco1 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Calcoco1 gene (NCBI Reference Sequence: NM_026192 ; Ensembl: ENSMUSG00000023055 ) is located on Mouse chromosome 15. 15 exons are identified, with the ATG start codon in exon 2 and the TGA stop codon in exon 15 (Transcript: ENSMUST00000023818). Exon 4 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Calcoco1 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-449K20 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 4 starts from about 12.54% of the coding region. The knockout of Exon 4 will result in frameshift of the gene. The size of intron 3 for 5'-loxP site insertion: 980 bp, and the size of intron 4 for 3'-loxP site insertion: 1414 bp. The size of effective cKO region: ~691 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 2 3 4 5 6 15 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Calcoco1 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. It may be difficult to construct this targeting vector. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(7191bp) | A(27.12% 1950) | C(22.63% 1627) | T(25.67% 1846) | G(24.59% 1768) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 3 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr15 - 102718244 102721243 3000 browser details YourSeq 254 1898 2429 3000 87.7% chr16 + 20667962 20668355 394 browser details YourSeq 249 1897 2444 3000 90.6% chr5 - 110239999 110240559 561 browser details YourSeq 238 1900 2437 3000 85.9% chr12 - 54084793 54085238 446 browser details YourSeq 238 1898 2436 3000 89.1% chr1 + 181875514 181876491 978 browser details YourSeq 234 1899 2429 3000 91.9% chr13 - 55216818 55217474 657 browser details YourSeq 233 1895 2411 3000 90.7% chr10 + 20292421 20293051 631 browser details YourSeq 225 1900 2444 3000 91.0% chr9 + 58244647 58245204 558 browser details YourSeq 191 1898 2436 3000 81.6% chr1 - 58563302 58563680 379 browser details YourSeq 180 1892 2468 3000 85.2% chr1 - 59542937 59543442 506 browser details YourSeq 175 1898 2361 3000 90.8% chr7 + 126507114 126507781 668 browser details YourSeq 175 1971 2401 3000 94.0% chr1 + 134476275 134476851 577 browser details YourSeq 173 1900 2415 3000 88.5% chr17 - 88499102 88499622 521 browser details YourSeq 163 1898 2392 3000 86.1% chr7 + 143581252 143581688 437 browser details YourSeq 159 1900 2335 3000 90.9% chr10 + 75225833 75226457 625 browser details YourSeq 157 1902 2332 3000 83.1% chr17 - 47510072 47510317 246 browser details YourSeq 156 1900 2392 3000 82.1% chr7 - 28281845 28282129 285 browser details YourSeq 156 1898 2457 3000 83.7% chr1 + 135335870 135336129 260 browser details YourSeq 153 1898 2075 3000 93.1% chr16 - 20346355 20346531 177 browser details YourSeq 152 1899 2308 3000 91.9% chr11 - 80344093 80344681 589 Note: The 3000 bp section upstream of Exon 4 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr15 - 102714553 102717552 3000 browser details YourSeq 134 2178 2628 3000 79.1% chrX + 8269231 8269486 256 browser details YourSeq 107 2509 2896 3000 80.8% chr9 - 61587274 61587517 244 browser details YourSeq 107 2469 2629 3000 90.1% chr7 - 26675721 26675880 160 browser details YourSeq 105 2460 2630 3000 83.9% chr9 + 110419223 110419384 162 browser details YourSeq 103 2465 2628 3000 86.6% chr14 - 96506585 96506744 160 browser details YourSeq 102 2459 2627 3000 89.0% chr13 - 80397016 80397183 168 browser details YourSeq 102 2465 2614 3000 82.6% chrX + 12199238 12199386 149 browser details YourSeq 101 2460 2629 3000 91.9% chr11 - 71809330 71809512 183 browser details YourSeq 100 2509 2631 3000 87.5% chr4 + 134794734 134794853 120 browser details YourSeq 98 2461 2584 3000 90.4% chr11 - 34954154 34954276 123 browser details YourSeq 98 2460 2626 3000 80.2% chr5 + 115585957 115586111 155 browser details YourSeq 97 2478 2628 3000 90.8% chr4 + 68759455 68759662 208 browser details YourSeq 94 2460 2631 3000 93.7% chr7 - 21434156 21434378 223 browser details YourSeq 94 2509 2633 3000 91.4% chr17 - 35117164 35117291 128 browser details YourSeq 93 2460 2580 3000 91.7% chr2 - 180325132 180325251 120 browser details YourSeq 93 2509 2619 3000 91.9% chr8 + 40932786 40932896 111 browser details YourSeq 92 2506 2627 3000 88.3% chr5 - 107065809 107065928 120 browser details YourSeq 92 2509 2628 3000 89.1% chrX + 140112753 140112870 118 browser details YourSeq 92 2474 2620 3000 85.0% chrX + 11478543 11478689 147 Note: The 3000 bp section downstream of Exon 4 is BLAT searched against the genome. No significant similarity is found. Page 4 of 8 https://www.alphaknockout.com Gene and protein information: Calcoco1 calcium binding and coiled coil domain 1 [ Mus musculus (house mouse) ] Gene ID: 67488, updated on 12-Aug-2019 Gene summary Official Symbol Calcoco1 provided by MGI Official Full Name calcium binding and coiled coil domain 1 provided by MGI Primary source MGI:MGI:1914738 See related Ensembl:ENSMUSG00000023055 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as Cocoa; Gcap11; mKIAA1536; 1810009B06Rik Expression Ubiquitous expression in lung adult (RPKM 33.2), heart adult (RPKM 30.0) and 28 other tissues See more Orthologs human all Genomic context Location: 15 F3; 15 See Calcoco1 in Genome Data Viewer Exon count: 15 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 15 NC_000081.6 (102706777..102722178, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 15 NC_000081.5 (102537208..102552609, complement) Chromosome 15 - NC_000081.6 Page 5 of 8 https://www.alphaknockout.com Transcript information: This gene has 9 transcripts Gene: Calcoco1 ENSMUSG00000023055 Description calcium binding and coiled coil domain 1 [Source:MGI Symbol;Acc:MGI:1914738] Gene Synonyms 1810009B06Rik, CoCoA, Gcap11 Location Chromosome 15: 102,706,777-102,722,178 reverse strand. GRCm38:CM001008.2 About this gene This gene has 9 transcripts (splice variants), 231 orthologues, 2 paralogues and is a member of 1 Ensembl protein family. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Calcoco1- ENSMUST00000023818.10 2824 691aa ENSMUSP00000023818.3 Protein coding CCDS27889 Q8CGU1 TSL:1 201 GENCODE basic APPRIS P1 Calcoco1- ENSMUST00000171838.1 2968 633aa ENSMUSP00000130170.1 Protein coding - E9Q7U2 TSL:1 204 GENCODE basic Calcoco1- ENSMUST00000229231.1 2226 606aa ENSMUSP00000155767.1 Protein coding - A0A2R8VKP5 GENCODE 205 basic Calcoco1- ENSMUST00000230035.1 1620 533aa ENSMUSP00000155446.1 Protein coding - A0A2R8VHU8 CDS 3' 207 incomplete Calcoco1- ENSMUST00000168112.7 1095 232aa ENSMUSP00000128307.1 Protein coding - F6Q5V4 CDS 5' 203 incomplete TSL:5 Calcoco1- ENSMUST00000229398.1 921 68aa ENSMUSP00000155415.1 Nonsense mediated - A0A2R8VKE2 - 206 decay Calcoco1- ENSMUST00000230374.1 1732 No - Retained intron - - - 208 protein Calcoco1- ENSMUST00000166943.1 863 No - Retained intron - - TSL:2 202 protein Calcoco1- ENSMUST00000230702.1 462 No - Retained intron - - - 209 protein Page 6 of 8 https://www.alphaknockout.com 35.40 kb Forward strand 102.70Mb 102.71Mb 102.72Mb 102.73Mb Contigs < AC123870.3 < AC124532.4 Genes (Comprehensive set... < Calcoco1-201protein coding < Calcoco1-203protein coding< Calcoco1-208retained intron < Calcoco1-205protein coding < Calcoco1-204protein coding < Calcoco1-209retained intron < Calcoco1-207protein coding < Calcoco1-202retained intron < Calcoco1-206nonsense mediated decay Regulatory Build 102.70Mb 102.71Mb 102.72Mb 102.73Mb Reverse strand 35.40 kb Regulation Legend CTCF Open Chromatin Promoter Promoter Flank Gene Legend Protein Coding merged Ensembl/Havana Ensembl protein coding Non-Protein Coding processed transcript Page 7 of 8 https://www.alphaknockout.com Transcript: ENSMUST00000023818 < Calcoco1-201protein coding Reverse strand 15.40 kb ENSMUSP00000023... MobiDB lite Low complexity (Seg) Coiled-coils (Ncoils) Superfamily SSF57997 Pfam SKICH domain Calcium binding and coiled-coil domain-like CALCOCO1/2, zinc finger-C2H2 domain PANTHER PTHR31915:SF5 PTHR31915 Gene3D 2.60.40.2840 3.30.160.550 All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend missense variant splice region variant synonymous variant Scale bar 0 60 120 180 240 300 360 420 480 540 600 691 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 8 of 8.
Recommended publications
  • Primate Specific Retrotransposons, Svas, in the Evolution of Networks That Alter Brain Function
    Title: Primate specific retrotransposons, SVAs, in the evolution of networks that alter brain function. Olga Vasieva1*, Sultan Cetiner1, Abigail Savage2, Gerald G. Schumann3, Vivien J Bubb2, John P Quinn2*, 1 Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, U.K 2 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK 3 Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, D-63225 Germany *. Corresponding author Olga Vasieva: Institute of Integrative Biology, Department of Comparative genomics, University of Liverpool, Liverpool, L69 7ZB, [email protected] ; Tel: (+44) 151 795 4456; FAX:(+44) 151 795 4406 John Quinn: Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK, [email protected]; Tel: (+44) 151 794 5498. Key words: SVA, trans-mobilisation, behaviour, brain, evolution, psychiatric disorders 1 Abstract The hominid-specific non-LTR retrotransposon termed SINE–VNTR–Alu (SVA) is the youngest of the transposable elements in the human genome. The propagation of the most ancient SVA type A took place about 13.5 Myrs ago, and the youngest SVA types appeared in the human genome after the chimpanzee divergence. Functional enrichment analysis of genes associated with SVA insertions demonstrated their strong link to multiple ontological categories attributed to brain function and the disorders. SVA types that expanded their presence in the human genome at different stages of hominoid life history were also associated with progressively evolving behavioural features that indicated a potential impact of SVA propagation on a cognitive ability of a modern human.
    [Show full text]
  • A Multi-Omics Interpretable Machine Learning Model Reveals Modes of Action of Small Molecules Natasha L
    www.nature.com/scientificreports OPEN A Multi-Omics Interpretable Machine Learning Model Reveals Modes of Action of Small Molecules Natasha L. Patel-Murray1, Miriam Adam2, Nhan Huynh2, Brook T. Wassie2, Pamela Milani2 & Ernest Fraenkel 2,3* High-throughput screening and gene signature analyses frequently identify lead therapeutic compounds with unknown modes of action (MoAs), and the resulting uncertainties can lead to the failure of clinical trials. We developed an approach for uncovering MoAs through an interpretable machine learning model of transcriptomics, epigenomics, metabolomics, and proteomics. Examining compounds with benefcial efects in models of Huntington’s Disease, we found common MoAs for compounds with unrelated structures, connectivity scores, and binding targets. The approach also predicted highly divergent MoAs for two FDA-approved antihistamines. We experimentally validated these efects, demonstrating that one antihistamine activates autophagy, while the other targets bioenergetics. The use of multiple omics was essential, as some MoAs were virtually undetectable in specifc assays. Our approach does not require reference compounds or large databases of experimental data in related systems and thus can be applied to the study of agents with uncharacterized MoAs and to rare or understudied diseases. Unknown modes of action of drug candidates can lead to unpredicted consequences on efectiveness and safety. Computational methods, such as the analysis of gene signatures, and high-throughput experimental methods have accelerated the discovery of lead compounds that afect a specifc target or phenotype1–3. However, these advances have not dramatically changed the rate of drug approvals. Between 2000 and 2015, 86% of drug can- didates failed to earn FDA approval, with toxicity or a lack of efcacy being common reasons for their clinical trial termination4,5.
    [Show full text]
  • Supplemental Information
    Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig.
    [Show full text]
  • Supplementary Table S2
    1-high in cerebrotropic Gene P-value patients Definition BCHE 2.00E-04 1 Butyrylcholinesterase PLCB2 2.00E-04 -1 Phospholipase C, beta 2 SF3B1 2.00E-04 -1 Splicing factor 3b, subunit 1 BCHE 0.00022 1 Butyrylcholinesterase ZNF721 0.00028 -1 Zinc finger protein 721 GNAI1 0.00044 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 GNAI1 0.00049 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 PDE1B 0.00069 -1 Phosphodiesterase 1B, calmodulin-dependent MCOLN2 0.00085 -1 Mucolipin 2 PGCP 0.00116 1 Plasma glutamate carboxypeptidase TMX4 0.00116 1 Thioredoxin-related transmembrane protein 4 C10orf11 0.00142 1 Chromosome 10 open reading frame 11 TRIM14 0.00156 -1 Tripartite motif-containing 14 APOBEC3D 0.00173 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D ANXA6 0.00185 -1 Annexin A6 NOS3 0.00209 -1 Nitric oxide synthase 3 SELI 0.00209 -1 Selenoprotein I NYNRIN 0.0023 -1 NYN domain and retroviral integrase containing ANKFY1 0.00253 -1 Ankyrin repeat and FYVE domain containing 1 APOBEC3F 0.00278 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F EBI2 0.00278 -1 Epstein-Barr virus induced gene 2 ETHE1 0.00278 1 Ethylmalonic encephalopathy 1 PDE7A 0.00278 -1 Phosphodiesterase 7A HLA-DOA 0.00305 -1 Major histocompatibility complex, class II, DO alpha SOX13 0.00305 1 SRY (sex determining region Y)-box 13 ABHD2 3.34E-03 1 Abhydrolase domain containing 2 MOCS2 0.00334 1 Molybdenum cofactor synthesis 2 TTLL6 0.00365 -1 Tubulin tyrosine ligase-like family, member 6 SHANK3 0.00394 -1 SH3 and multiple ankyrin repeat domains 3 ADCY4 0.004 -1 Adenylate cyclase 4 CD3D 0.004 -1 CD3d molecule, delta (CD3-TCR complex) (CD3D), transcript variant 1, mRNA.
    [Show full text]
  • Screening and Association Testing of Common Coding Variation in Steroid
    BMC Cancer BioMed Central Research article Open Access Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort Christopher A Haiman*1, Rachel R Garcia1, Chris Hsu1, Lucy Xia1, Helen Ha2, Xin Sheng1, Loic Le Marchand3, Laurence N Kolonel3, Brian E Henderson1, Michael R Stallcup4, Geoffrey L Greene5 and Michael F Press6 Address: 1Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA, 2Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, USA, 3Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii, USA, 4Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA, 5The Ben May Department for Cancer Research, The University of Chicago, Chicago Illinois, USA and 6Department of Pathology, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA Email: Christopher A Haiman* - [email protected]; Rachel R Garcia - [email protected]; Chris Hsu - [email protected]; Lucy Xia - [email protected]; Helen Ha - [email protected]; Xin Sheng - [email protected]; Loic Le Marchand - [email protected]; Laurence N Kolonel - [email protected]; Brian E Henderson - [email protected]; Michael R Stallcup - [email protected]; Geoffrey L Greene - [email protected]; Michael F Press - [email protected] * Corresponding author Published: 30 January 2009 Received: 26 November 2008 Accepted: 30 January 2009 BMC Cancer 2009, 9:43 doi:10.1186/1471-2407-9-43 This article is available from: http://www.biomedcentral.com/1471-2407/9/43 © 2009 Haiman et al; licensee BioMed Central Ltd.
    [Show full text]
  • Using Mrna Deep Sequencing to Analyze Differentially Expressed Genes During Panax Notoginseng Saponin Treatment of Ischemic Stroke
    MOLECULAR MEDICINE REPORTS 22: 4743-4753, 2020 Using mRNA deep sequencing to analyze differentially expressed genes during Panax notoginseng saponin treatment of ischemic stroke JUN LIN, PING LIANG, QING HUANG, CHONGDONG JIAN, JIANMIN HUANG, XIONGLIN TANG, XUEBIN LI, YANLING LIAO, XIAOHUA HUANG, WENHUA HUANG, LI SU And LANQING MENG Department of Neurology, Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi Zhuang Autonomous Region 533000, P.R. China Received October 30, 2019; Accepted August 10, 2020 DOI: 10.3892/mmr.2020.11550 Abstract. Treatment with Panax notoginseng saponin (PNS) growth factor receptor 2. In conclusion, these genes may be can prevent neurological damage in middle cerebral artery important in the underlying mechanism of PNS treatment occlusion model rats to promote recovery after a stroke. in ischemic stroke. Additionally, the present data provided However, the exact molecular mechanisms are unknown and novel insight into the pathogenesis of ischemic stroke. require further study. In the present study, mRNA sequencing was employed to investigate differential gene expression Introduction between model and sham groups, and between model and PNS-treated groups. Enrichment of gene data was performed Stroke is the second leading cause of death and disability using Gene Ontology analysis and the Kyoto Encyclopedia worldwide (1). Ischemic stroke, which accounts for 80% of all of Genes and Genomes database. Hub genes were identi- strokes, usually causes severe neuronal damage and secondary fied and networks were constructed using Cytoscape that neuronal death (2). Cerebral ischemia and reperfusion injury were further verified by reverse transcription‑quantitative are complex pathological processes that involve inflamma- PCR.
    [Show full text]
  • Supplementary Table 1. List of Genes Up-Regulated in Abiraterone-Resistant Vcap Xenograft Samples PIK3IP1 Phosphoinositide-3-Kin
    Supplementary Table 1. List of genes up-regulated in abiraterone-resistant VCaP xenograft samples PIK3IP1 phosphoinositide-3-kinase interacting protein 1 TMEM45A transmembrane protein 45A THBS1 thrombospondin 1 C7orf63 chromosome 7 open reading frame 63 OPTN optineurin FAM49A family with sequence similarity 49, member A APOL4 apolipoprotein L, 4 C17orf108|LOC201229 chromosome 17 open reading frame 108 | hypothetical protein LOC201229 SNORD94 small nucleolar RNA, C/D box 94 PCDHB11 protocadherin beta 11 RBM11 RNA binding motif protein 11 C6orf225 chromosome 6 open reading frame 225 KIAA1984|C9orf86|TMEM14 1 KIAA1984 | chromosome 9 open reading frame 86 | transmembrane protein 141 KIAA1107 TLR3 toll-like receptor 3 LPAR6 lysophosphatidic acid receptor 6 KIAA1683 GRB10 growth factor receptor-bound protein 10 TIMP2 TIMP metallopeptidase inhibitor 2 CCDC28A coiled-coil domain containing 28A FBXL2 F-box and leucine-rich repeat protein 2 NOV nephroblastoma overexpressed gene TSPAN31 tetraspanin 31 NR3C2 nuclear receptor subfamily 3, group C, member 2 DYNC2LI1 dynein, cytoplasmic 2, light intermediate chain 1 C15orf51 dynamin 1 pseudogene SAMD13 sterile alpha motif domain containing 13 RASSF6 Ras association (RalGDS/AF-6) domain family member 6 ZNF167 zinc finger protein 167 GATA2 GATA binding protein 2 NUDT7 nudix (nucleoside diphosphate linked moiety X)-type motif 7 DNAJC18 DnaJ (Hsp40) homolog, subfamily C, member 18 SNORA57 small nucleolar RNA, H/ACA box 57 CALCOCO1 calcium binding and coiled-coil domain 1 RLN2 relaxin 2 ING4 inhibitor of
    [Show full text]
  • PRC1 and PRC2 Are Not Required for Targeting of H2A.Z to Developmental Genes in Embryonic Stem Cells
    PRC1 and PRC2 Are Not Required for Targeting of H2A.Z to Developmental Genes in Embryonic Stem Cells Robert S. Illingworth1, Catherine H. Botting2, Graeme R. Grimes1, Wendy A. Bickmore1*, Ragnhild Eskeland1*¤ 1 MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine at the University of Edinburgh, Edinburgh, United Kingdom, 2 BMS Mass Spectrometry and Proteomics Facility, Biomedical Sciences Research Complex, University of St. Andrews, St. Andrews, Fife, United Kingdom Abstract The essential histone variant H2A.Z localises to both active and silent chromatin sites. In embryonic stem cells (ESCs), H2A.Z is also reported to co-localise with polycomb repressive complex 2 (PRC2) at developmentally silenced genes. The mechanism of H2A.Z targeting is not clear, but a role for the PRC2 component Suz12 has been suggested. Given this association, we wished to determine if polycomb functionally directs H2A.Z incorporation in ESCs. We demonstrate that the PRC1 component Ring1B interacts with multiple complexes in ESCs. Moreover, we show that although the genomic distribution of H2A.Z co-localises with PRC2, Ring1B and with the presence of CpG islands, H2A.Z still blankets polycomb target loci in the absence of Suz12, Eed (PRC2) or Ring1B (PRC1). Therefore we conclude that H2A.Z accumulates at developmentally silenced genes in ESCs in a polycomb independent manner. Citation: Illingworth RS, Botting CH, Grimes GR, Bickmore WA, Eskeland R (2012) PRC1 and PRC2 Are Not Required for Targeting of H2A.Z to Developmental Genes in Embryonic Stem Cells. PLoS ONE 7(4): e34848. doi:10.1371/journal.pone.0034848 Editor: Robert Feil, CNRS, France Received October 8, 2011; Accepted March 9, 2012; Published April 9, 2012 Copyright: ß 2012 Illingworth et al.
    [Show full text]
  • Supplementary Table 1 Double Treatment Vs Single Treatment
    Supplementary table 1 Double treatment vs single treatment Probe ID Symbol Gene name P value Fold change TC0500007292.hg.1 NIM1K NIM1 serine/threonine protein kinase 1.05E-04 5.02 HTA2-neg-47424007_st NA NA 3.44E-03 4.11 HTA2-pos-3475282_st NA NA 3.30E-03 3.24 TC0X00007013.hg.1 MPC1L mitochondrial pyruvate carrier 1-like 5.22E-03 3.21 TC0200010447.hg.1 CASP8 caspase 8, apoptosis-related cysteine peptidase 3.54E-03 2.46 TC0400008390.hg.1 LRIT3 leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 1.86E-03 2.41 TC1700011905.hg.1 DNAH17 dynein, axonemal, heavy chain 17 1.81E-04 2.40 TC0600012064.hg.1 GCM1 glial cells missing homolog 1 (Drosophila) 2.81E-03 2.39 TC0100015789.hg.1 POGZ Transcript Identified by AceView, Entrez Gene ID(s) 23126 3.64E-04 2.38 TC1300010039.hg.1 NEK5 NIMA-related kinase 5 3.39E-03 2.36 TC0900008222.hg.1 STX17 syntaxin 17 1.08E-03 2.29 TC1700012355.hg.1 KRBA2 KRAB-A domain containing 2 5.98E-03 2.28 HTA2-neg-47424044_st NA NA 5.94E-03 2.24 HTA2-neg-47424360_st NA NA 2.12E-03 2.22 TC0800010802.hg.1 C8orf89 chromosome 8 open reading frame 89 6.51E-04 2.20 TC1500010745.hg.1 POLR2M polymerase (RNA) II (DNA directed) polypeptide M 5.19E-03 2.20 TC1500007409.hg.1 GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type 6.48E-03 2.17 TC2200007132.hg.1 RFPL3 ret finger protein-like 3 5.91E-05 2.17 HTA2-neg-47424024_st NA NA 2.45E-03 2.16 TC0200010474.hg.1 KIAA2012 KIAA2012 5.20E-03 2.16 TC1100007216.hg.1 PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 7.43E-03 2.15 TC0400012977.hg.1 SH3D19
    [Show full text]
  • Genome Wide Study of Tardive Dyskinesia in Schizophrenia
    Lim et al. Translational Psychiatry (2021) 11:351 https://doi.org/10.1038/s41398-021-01471-y Translational Psychiatry ARTICLE Open Access Genome wide study of tardive dyskinesia in schizophrenia Keane Lim 1, Max Lam 1,2,3, Clement Zai4,JennyTay1, Nina Karlsson5,SmitaN.Deshpande6,B.K.Thelma7, Norio Ozaki 8,ToshiyaInada 9,KangSim 1,10, Siow-Ann Chong1,11,ToddLencz 2,3,12,JianjunLiu 5,13 and Jimmy Lee 1,11,14 Abstract Tardive dyskinesia (TD) is a severe condition characterized by repetitive involuntary movement of orofacial regions and extremities. Patients treated with antipsychotics typically present with TD symptomatology. Here, we conducted the largest GWAS of TD to date, by meta-analyzing samples of East-Asian, European, and African American ancestry, followed by analyses of biological pathways and polygenic risk with related phenotypes. We identified a novel locus and three suggestive loci, implicating immune-related pathways. Through integrating trans-ethnic fine mapping, we identified putative credible causal variants for three of the loci. Post-hoc analysis revealed that SNPs harbored in TNFRSF1B and CALCOCO1 independently conferred three-fold increase in TD risk, beyond clinical risk factors like Age of onset and Duration of illness to schizophrenia. Further work is necessary to replicate loci that are reported in the study and evaluate the polygenic architecture underlying TD. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Introduction more severe schizophrenia illness, cognitive impairments, – Tardive Dyskinesia (TD) is a persistent and potentially lowered quality of life and increased mortality7 10. debilitating involuntary movement disorder characterized The pathophysiology of TD is currently unknown. by choreiform, athetoid, and or dystonic movements1,2.
    [Show full text]
  • Npgrj Ng 406 1..8
    ARTICLES The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling Sari Tuupanen1, Mikko Turunen2,3, Rainer Lehtonen1, Outi Hallikas2,3, Sakari Vanharanta1,12, Teemu Kivioja2–4, Mikael Bjo¨rklund2,3, Gonghong Wei2,3, Jian Yan2,3, Iina Niittyma¨ki1, Jukka-Pekka Mecklin5, Heikki Ja¨rvinen6, Ari Ristima¨ki7–9, Mariachiara Di-Bernardo10, Phil East11, Luis Carvajal-Carmona11, Richard S Houlston10, Ian Tomlinson11, Kimmo Palin4,12, Esko Ukkonen4, Auli Karhu1, Jussi Taipale2,3 & Lauri A Aaltonen1 Homozygosity for the G allele of rs6983267 at 8q24 increases colorectal cancer (CRC) risk B1.5 fold. We report here that the risk allele G shows copy number increase during CRC development. Our computer algorithm, Enhancer Element Locator (EEL), identified an enhancer element that contains rs6983267. The element drove expression of a reporter gene in a pattern that is consistent with regulation by the key CRC pathway Wnt. rs6983267 affects a binding site for the Wnt-regulated transcription factor TCF4, with the risk allele G showing stronger binding in vitro and in vivo. Genome-wide ChIP assay revealed the element as the strongest TCF4 binding site within 1 Mb of MYC. An unambiguous correlation between rs6983267 genotype and MYC expression was not detected, and additional work is required to scrutinize all possible targets of the enhancer. Our work provides evidence that the common CRC predisposition associated with 8q24 arises from enhanced responsiveness to Wnt signaling. Genome-wide association studies (GWAS) are a powerful way to obvious pathogenic changes14. The nearest protein-coding gene, MYC, identify disease susceptibility variants1,2.
    [Show full text]
  • Downloaded from Ensembl
    UCSF UC San Francisco Electronic Theses and Dissertations Title Detecting genetic similarity between complex human traits by exploring their common molecular mechanism Permalink https://escholarship.org/uc/item/1k40s443 Author Gu, Jialiang Publication Date 2019 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California by Submitted in partial satisfaction of the requirements for degree of in in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, SAN FRANCISCO AND UNIVERSITY OF CALIFORNIA, BERKELEY Approved: ______________________________________________________________________________ Chair ______________________________________________________________________________ ______________________________________________________________________________ ______________________________________________________________________________ ______________________________________________________________________________ Committee Members ii Acknowledgement This project would not have been possible without Prof. Dr. Hao Li, Dr. Jiashun Zheng and Dr. Chris Fuller at the University of California, San Francisco (UCSF) and Caribou Bioscience. The Li lab grew into a multi-facet research group consist of both experimentalists and computational biologists covering three research areas including cellular/molecular mechanism of ageing, genetic determinants of complex human traits and structure, function, evolution of gene regulatory network. Labs like these are the pillar of global success and reputation
    [Show full text]